Dassault Systèmes has reaffirmed its 2026 financial outlook while announcing a significant acquisition aimed at enhancing its AI capabilities in the life sciences sector.
The French software giant reported second-quarter revenues of €1.56 billion (approximately $1.80 billion), reflecting a 4% increase at constant currencies, largely fueled by growth in subscription and cloud software sales. In a strategic move to bolster its position in the life sciences domain, Dassault Systèmes plans to acquire U.S.-based ArisGlobal for around $1.8 billion, with potential additional payments tied to future AI revenue milestones. This acquisition is expected to close in the latter half of 2026, pending regulatory approvals.
The integration of ArisGlobal is particularly timely as the demand for AI-driven solutions in clinical development and patient safety monitoring continues to rise among drug manufacturers. Despite challenges in its Life Sciences segment, where revenue declined by 4% in the second quarter, Dassault's core industrial software business remains robust, with a notable 14% increase in cloud software revenue. The company’s performance varied by region, with the Americas and Asia showing growth, while Europe faced stagnation due to a downturn in the automotive sector.
This acquisition not only positions Dassault to better meet the evolving needs of the life sciences industry but also aims to enhance revenue growth and earnings per share shortly after the deal's completion. As AI continues to reshape healthcare, this strategic investment could significantly impact the future landscape of clinical software solutions.